Kidney (Renal Cell) Cancer
Featured Articles
(Curetoday.com) May 15, 2019 - The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma. Of note, this is the first FDA approval of an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC.
Read Article
(Exelixis) May 1, 2019 - Exelixis, Inc. today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with nivolumab (Opdivo®) and ipilimumab (Yervoy®) versus nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or...
Read Article
Latest Articles
May 16, 2019
May 15, 2019
May 15, 2019
May 08, 2019
April 30, 2019
April 30, 2019
April 22, 2019
April 22, 2019
View More
News Commentary
There is no Kidney (Renal Cell) Cancer commentary.

OBR Blog
As the Genitourinary Cancers (GU) Symposium gets under way in San Francisco February 13-16 2019, at a pre-meeting... Read more
February 11, 2019